Chakravarti Sachiv, Gupta Sneha R, Myneni Saket, Elshareif Mazin, Rogers James L, Caraway Chad, Ahmed A Karim, Schreck Karisa C, Kamson David O, Holdhoff Matthias, Croog Victoria, Redmond Kristin J, Bettegowda Chetan, Mukherjee Debraj
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cancers (Basel). 2025 May 14;17(10):1659. doi: 10.3390/cancers17101659.
In recent times, a greater emphasis has been placed on framing patient clinical assessments and QOL as both endpoints and prognostic factors for neuro-oncological care. However, there is currently a lack of consensus on the most effective metrics and instruments for use in patients with primary brain tumors. Due to the heterogeneity in clinical characteristics, histological classification, anatomical location, and available treatment modalities for glioma, quantifying patient clinical condition and QOL within this unique population is particularly challenging. In this paper, we comprehensively review the available literature on the use of clinical assessment tools in glioma patients, highlighting the strengths and limitations of prominent instruments. We demonstrate that clinical outcome assessment (COA) instruments provide valuable and complementary insights into the physical, psychological, and spiritual well-being of glioma patients.
近年来,人们更加重视将患者的临床评估和生活质量作为神经肿瘤护理的终点指标和预后因素。然而,目前对于原发性脑肿瘤患者最有效的评估指标和工具尚无共识。由于胶质瘤患者在临床特征、组织学分类、解剖位置和可用治疗方式方面存在异质性,在这一独特人群中量化患者的临床状况和生活质量尤其具有挑战性。在本文中,我们全面回顾了关于胶质瘤患者临床评估工具使用的现有文献,突出了主要工具的优势和局限性。我们证明,临床结局评估(COA)工具为胶质瘤患者的身体、心理和精神健康提供了有价值的补充见解。